{"nctId":"NCT01722240","briefTitle":"Liraglutide in Type 1 Diabetes","startDateStruct":{"date":"2012-11-01","type":"ACTUAL"},"conditions":["Type 1 Diabetes"],"count":69,"armGroups":[{"label":"Liraglutide 1.8mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Liraglutide 1.8mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Liraglutide 1.8mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII; also known as insulin pump) or multiple (four or more) injections of insulin per day.\n2. Regularly measuring blood sugars four times daily.\n3. HbA1c of less than 8.5%.\n4. Well versed with carbohydrate counting.\n5. Age 18-75 years.\n6. BMI 20-40 kg/m2\n\nExclusion Criteria:\n\n1. Type 1 diabetes for less than 6 months;\n2. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks;\n3. Hepatic disease (transaminase \\> 3 times normal) or cirrhosis;\n4. Renal impairment (serum eGFR \\< 30ml/min/1.73m2);\n5. HIV or Hepatitis B or C positive status;\n6. Participation in any other concurrent clinical trial;\n7. Any other life-threatening, non-cardiac disease;\n8. Use of an investigational agent or therapeutic regimen within 30 days of study.\n9. history of pancreatitis\n10. pregnancy\n11. inability to give informed consent\n12. history of gastroparesis\n13. history of medullary thyroid carcinoma or MEN 2 syndrome.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c (%)","description":"HbA1c measured at baseline and after 52 weeks of treatment with Liraglutide or placebo.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.92","spread":"0.15"},{"groupId":"OG001","value":"7.48","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.45","spread":"0.12"},{"groupId":"OG001","value":"7.58","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Mean Weekly Glucose Concentrations.","description":"Mean weekly glucose concentrations measured by CGM at baseline and at 52 weeks","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":"5"},{"groupId":"OG001","value":"160","spread":"6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":"6"},{"groupId":"OG001","value":"156","spread":"6"}]}]}]},{"type":"SECONDARY","title":"Body Weight","description":"Body weight in Kg measured at weeks 0 (baseline) and at 52 weeks after treatment with liraglutide or placebo","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":"3.8"},{"groupId":"OG001","value":"84.1","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":"3.8"},{"groupId":"OG001","value":"83.8","spread":"4.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":[]}}}